Breast Cancer

Single-Agent Talazoparib Shows Activity in the Neoadjuvant Treatment of Triple-Negative Breast Cancer

For the neoadjuvant treatment of triple-negative breast cancer, the oral poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib...

Multiple Myeloma

FDA Alert: Clinical Trial Results Show an Increased Risk of Death Associated With Melphalan Flufenamide

The U.S. Food and Drug Administration (FDA) is alerting patients and health-care professionals that a clinical trial (OCEAN, Study OP-103)...


ASTRO Issues New Clinical Guideline on Radiation Therapy for Adult Patients With Soft-Tissue Sarcoma

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) published in Practical Radiation Oncology provides guidance... 

Breast Cancer

Study Explores Rates of Reconstruction for Women With Inflammatory Breast Cancer Undergoing Mastectomy

The percentage of patients with inflammatory breast cancer who select reconstructive surgery after mastectomy—whether immediate or delayed...


ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...


Issues in Oncology

Matthew G. Vander Heiden, MD, PhD, and Karen H. Vousden, PhD: A Conversation About the Role of Diet in Cancer

Hematologic Malignancies
Symptom Management

Third-Party BK Virus–Specific Cytotoxic T-Lymphocyte Therapy for BK Virus–Associated Hemorrhagic Cystitis After Stem Cell Transplant

In a single-institution phase II trial reported in the Journal of Clinical Oncology, Olson et al found that high rates of response were achieved with third-party BK virus–specific cytotoxic T-lymphocyte therapy (BKV-CTL) in patients with BK virus–associated hemorrhagic cystitis after allogeneic...


Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Breast Cancer

Sibylle Loibl, MD, PhD, on Triple-Negative Breast Cancer: Improving Long-Term Outcomes With Durvalumab

Gynecologic Cancers

OUTBACK Trial: No Survival Benefit With Adjuvant Chemotherapy After Standard Chemoradiation for Locally Advanced Cervical Cancer

Cervical cancer is the fourth most common cancer in women worldwide, and the leading cause of cancer-related death among women in Eastern, Western, Middle, and Southern Africa. Globally, in 2018, approximately 570,000 women were diagnosed with cervical cancer, and 311,000 women died. In the United...


Remote Monitoring Program Reduced Hospitalization Among Patients With Cancer Infected With COVID-19

A study by researchers at Mayo Clinic Cancer Center found that patients with cancer diagnosed with COVID-19 who received care at home via remote patient monitoring were significantly less likely to require hospitalization for their illness, compared to patients with cancer infected with the virus...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Prostate Cancer

Karim Fizazi, MD, PhD, on Prostate Cancer: Abiraterone Acetate, Prednisone, and Radiotherapy in Metastatic Disease

Lung Cancer

Pralsetinib in Advanced RET Fusion–Positive NSCLC: ARROW Trial

As reported in The Lancet Oncology by Justin F. Gainor, MD, and colleagues, an interim analysis of the phase I/II ARROW trial has shown that the oral RET inhibitor pralsetinib produced high response rates in previously treated and treatment-naive patients with advanced RET fusion–positive non–small ...


Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...